[News] MSM in England to be offered free HPV vaccination
On Feb 5, 2018, Public Health England (PHE) announced that from April 2018, men who have sex with men (MSM), aged 45 years and younger in England, will be offered free vaccination against human papillomavirus (HPV) infection through their local sexual health clinic. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Tony Kirby Tags: News Source Type: research
[Articles] Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Our results suggest that in patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy. These results have implications for the design of future clinical trials for patients with metastatic melanoma and the magnitude of the benefit found supports further investigation of the underlying mechanism of these associations. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 12, 2018 Category: Cancer & Oncology Authors: Jennifer L McQuade, Carrie R Daniel, Kenneth R Hess, Carmen Mak, Daniel Y Wang, Rajat R Rai, John J Park, Lauren E Haydu, Christine Spencer, Matthew Wongchenko, Stephen Lane, Dung-Yang Lee, Mathilde Kaper, Meredith McKean, Kathryn E Beckermann, Samuel M R Tags: Articles Source Type: research
[Articles] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Adjuvant chemotherapy given during and after radiotherapy for high-risk endometrial cancer did not improve 5-year overall survival, although it did increase failure-free survival. Women with high-risk endometrial cancer should be individually counselled about this combined treatment. Continued follow-up is needed to evaluate long-term survival. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 12, 2018 Category: Cancer & Oncology Authors: Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B Ottevanger, Jonathan A Ledermann, Pearly Khaw, Alessandro Colombo, Anthony Fyles, Marie-Helene Baron, Ina M J ürgenliemk-Schulz Tags: Articles Source Type: research
[Comment] BMI and outcomes in melanoma: more evidence for the obesity paradox
The association between increased body-mass index (BMI) and the risk of developing and dying from cancer has been recognised across a broad range of tumour types.1,2 The magnitude of this association is so great that in the USA obesity is considered to be the major preventable cause of cancer.3 However, data regarding the effect of obesity on the outcomes of patients undergoing cancer treatment is less clear. Several observational studies in different tumour types have shown that a moderately increased BMI (compared with an optimal BMI of 22 ·5 kg/m2) is associated with improved outcomes both around the time of treatment ...
Source: The Lancet Oncology - February 12, 2018 Category: Cancer & Oncology Authors: Andrew J Hayes, James Larkin Tags: Comment Source Type: research
[Comment] Adjuvant therapy for women with high-risk endometrial carcinoma
Identification of optimal therapy for patients with high-risk endometrial carcinoma has been frustrated by near-dichotomous paradigms of surgical treatment in the international community and a scarcity of level 1 data to inform adjuvant treatment. For example, at a meeting of the European Society for Medical Oncology –European Society of Gynaecological Oncology–European Society for Radiotherapy and Oncology Endometrial Consensus Conference Working Group, 14 recommendations were supported by level 1 or 2 evidence out of 50 nonsurgical treatment topics. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 12, 2018 Category: Cancer & Oncology Authors: Sean C Dowdy, Gretchen E Glaser Tags: Comment Source Type: research
[Articles] Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
The treatment combination of axitinib plus pembrolizumab is tolerable and shows promising antitumour activity in patients with treatment-naive advanced renal cell carcinoma. Whether or not the combination works better than a sequence of VEGF pathway inhibition followed by an anti-PD-1 therapy awaits the completion of a phase 3 trial comparing axitinib plus pembrolizumab with sunitinib monotherapy (NCT02853331). (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 10, 2018 Category: Cancer & Oncology Authors: Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, Mayer N Fishman, David F McDermott, Daniel C Cho, Ulka Vaishampayan, Saby George, Thomas E Olencki, Jamal C Tarazi, Brad Rosbrook, Kathrine C Fernandez, Mariajose Lechuga, Toni K Choueiri Tags: Articles Source Type: research
[Comment] Combination therapies for patients with metastatic renal cell carcinoma
In the past decade, several single drugs have been approved for the treatment of metastatic renal cell carcinoma, with substantial benefits in disease control, resolution of symptoms, and survival for the patients.1 In the meantime, only two combination therapies, bevacizumab plus interferon-alfa as first-line treatment and lenvatinib plus everolimus in the second-line setting, have been approved on the basis of a better outcome and an acceptable toxicity over single drugs.2,3 The poor tolerability and absence of predictive biomarkers for treatment response represented major issues in the development of combination strateg...
Source: The Lancet Oncology - February 10, 2018 Category: Cancer & Oncology Authors: Giuseppe Procopio, Raffaele Ratta, Filippo de Braud, Elena Verzoni Tags: Comment Source Type: research
[Articles] Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group
Addition of metronomic oral cyclophosphamide to trastuzumab plus pertuzumab in older and frail patients with HER2-positive metastatic breast cancer increased median progression-free survival by 7 months compared with dual HER2 blockade alone, with an acceptable safety profile. Trastuzumab and pertuzumab plus metronomic oral cyclophosphamide, followed by trastuzumab emtansine after disease progression, might delay or supersede the need for taxane chemotherapy in this population. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 9, 2018 Category: Cancer & Oncology Authors: Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, Peter Vuylsteke, Giuseppe Curigliano, Simon Waters, Barbara Brouwers, Sevilay Altintas, Nathan Touati, Fatima Cardoso, Etienne Brain Tags: Articles Source Type: research
[Comment] Clinical trials in older, less fit populations: an unmet need?
Hans Wildiers and colleagues1 are to be congratulated on their demonstration of a framework for clinical trials in older, more frail patients with HER-positive metastatic breast cancer. Clinical trials are a global prerequisite for establishing new treatment standards, but eligibility criteria generally restrict participation to fit populations with minimal comorbidities. These criteria contribute to underrepresentation of older populations with functional limitations in most clinical trials. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 9, 2018 Category: Cancer & Oncology Authors: Charles E Geyer Tags: Comment Source Type: research
[Articles] Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
In patients with newly diagnosed multiple myeloma, denosumab was non-inferior to zoledronic acid for time to skeletal-related events. The results from this study suggest denosumab could be an additional option for the standard of care for patients with multiple myeloma with bone disease. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher, Kazuyuki Shimizu, Ram ón García-Sanz, Brian Durie, Wojciech Legieć, Marta Krejčí, Kamel Laribi, Li Zhu, Paul Cheng, Douglas Warner, G David Roodman Tags: Articles Source Type: research
[News] Cancer-related productivity losses in BRICS countries
The costs of cancer include loss of productivity —ie, the loss of an individual's contribution to the market economy because of their premature death from cancer. These costs have been assessed in high-income regions such as Europe and the USA. Now, for the first time, a study has assessed the cost of lost productivity due to cancer in Brazil, R ussia, India, China, and South Africa (the BRICS countries). (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Priya Venkatesan Tags: News Source Type: research
[News] Selinexor and dexamethasone in multiple myeloma
Combined treatment with selinexor and dexamethasone shows encouraging activity in patients with highly refractory multiple myeloma, according to a phase 2 trial. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Talha Khan Burki Tags: News Source Type: research
[News] Tumour-treating fields complement glioblastoma treatment
The addition of tumour-treating fields to standard gioblastoma therapy improves progression-free survival (PFS) and does not negatively affect patients' health-related quality of life (HRQoL), according to recent findings. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Elizabeth Gourd Tags: News Source Type: research
[News] CAR T-cells for relapsed B-cell ALL in children and young adults
Results of a phase 2 single-cohort clinical trial show that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel provides durable remission with long-term persistence in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Robert Stirrups Tags: News Source Type: research
[News] CAR T-cells for relapsed B-cell ALL in adults
Adults with relapsed B-cell acute lymphoblastic leukaemia (ALL) might achieve durable responses to chimeric antigen receptor (CAR) T-cell therapy, according to recent findings. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Judith A Gilbert Tags: News Source Type: research
